Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Alfasigma","sponsor":"PhaseBio Pharmaceuticals","pharmaFlowCategory":"D","amount":"$245.0 million","upfrontCash":"$20.0 million","newsHeadline":"Alfasigma Buys Back its European License for Bentracimab from PhaseBio","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"ITALY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Intercept Pharmaceuticals","pharmaFlowCategory":"D","amount":"$794.0 million","upfrontCash":"$794.0 million","newsHeadline":"Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Intercept Pharmaceuticals","pharmaFlowCategory":"D","amount":"$794.0 million","upfrontCash":"$794.0 million","newsHeadline":"Alfasigma Completes Acquisition of Intercept Pharmaceuticals, Inc.","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"$229.7 million","upfrontCash":"$54.7 million","newsHeadline":"Galapagos Signs Agreement to Transfer Jyseleca\u00ae Business to Alfasigma","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"$184.9 million","upfrontCash":"$54.3 million","newsHeadline":"Galapagos Completes Transaction to Transfer Jyseleca\u00ae Business to Alfasigma","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Alfasigma

    Menu

    Alfasigma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Alfasigma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Galapagos Completes Transaction to Transfer Jyseleca® Business to Alfasigma

              Details:

              Alfasigma completed acquisition of Jyseleca (filgotinib), which provides European and UK Marketing Authorizations. It is used for the treatment of moderate to severe rheumatoid arthritis.

              Lead Product(s): Filgotinib

              Therapeutic Area: Immunology Product Name: Jyseleca

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Galapagos

              Deal Size: $184.9 million Upfront Cash: $54.3 million

              Deal Type: Acquisition January 31, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Alfasigma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Galapagos Signs Agreement to Transfer Jyseleca® Business to Alfasigma

              Details:

              The agreement aims to transfer Galapagos’ Jyseleca (filgotinib maleate) business to Alfasigma, marking a significant milestone in its transformation into an innovative biotechnology company with a pipeline aimed for immunology and oncology.

              Lead Product(s): Filgotinib

              Therapeutic Area: Immunology Product Name: Jyseleca

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Galapagos

              Deal Size: $229.7 million Upfront Cash: $54.7 million

              Deal Type: Agreement January 02, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Alfasigma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Alfasigma Completes Acquisition of Intercept Pharmaceuticals, Inc.

              Details:

              Through the acquisition, Alfasigma adds Ocaliva (obeticholic acid), a farnesoid X receptor agonist approved in the United States for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA.

              Lead Product(s): Obeticholic Acid

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Ocaliva

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Intercept Pharmaceuticals

              Deal Size: $794.0 million Upfront Cash: $794.0 million

              Deal Type: Acquisition November 08, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Alfasigma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases

              Details:

              Through the acquisition, Alfasigma adds Ocaliva (obeticholic acid), a farnesoid X receptor agonist approved in the United States for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA.

              Lead Product(s): Obeticholic Acid,Ursodeoxycholic Acid

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Ocaliva

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Intercept Pharmaceuticals

              Deal Size: $794.0 million Upfront Cash: $794.0 million

              Deal Type: Acquisition September 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Alfasigma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Alfasigma Buys Back its European License for Bentracimab from PhaseBio

              Details:

              Bentracimab is a new human monoclonal antibody fragment which in previous clinical studies has shown an immediate and prolonged reversal of the antiplatelet effects of Brilinta® / Brilique® (ticagrelor).

              Lead Product(s): Bentracimab

              Therapeutic Area: Hematology Product Name: PB2452

              Highest Development Status: Phase III Product Type: Large molecule

              Recipient: PhaseBio Pharmaceuticals

              Deal Size: $245.0 million Upfront Cash: $20.0 million

              Deal Type: Acquisition June 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY